Wikisage, the free encyclopedia of the second generation, is digital heritage
Neurocysticercosis: Difference between revisions
Jump to navigation
Jump to search
(type err) |
m (→Weblinks) |
||
| Line 15: | Line 15: | ||
[http://austinpublishinggroup.com/clinical-neurology/fulltext/ajcn-v1-id1013.php Immunological and Endocrine Profile of Two Patients with Severe Subarachnoid Neurocysticercosis, Resistant to the Cysticidal Treatment] | [http://austinpublishinggroup.com/clinical-neurology/fulltext/ajcn-v1-id1013.php Immunological and Endocrine Profile of Two Patients with Severe Subarachnoid Neurocysticercosis, Resistant to the Cysticidal Treatment] | ||
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458580/pdf/hjmph7606_0152.pdf Headaches More Common among Epilepsy Sufferers with Neurocysticercosis than Other Structural Brain Lesions] | |||
<references/> | <references/> | ||
Revision as of 19:14, 20 June 2017
Neurocysticercosis is a contributor of late onset epilepsy[1]
Disease classification WHO
B 69.0 neurocysticercosis
Several studies have reported an association between epilepsy and NC based on positive serum antibodies against Taenia solium, which has distorted the perception of the epidemiology of epilepsy related to NC. Immunoserologic assays, such as enzyme-linked immunoelectrotransfer blot assay (EITB) or enzyme-linked immunosorbent assay (ELISA), detect antibodies against T. solium
